பார்மா வாய்ப்புகள் நிதி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from பார்மா வாய்ப்புகள் நிதி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In பார்மா வாய்ப்புகள் நிதி Today - Breaking & Trending Today

Mycovia Pharmaceuticals Submits New Drug Application to the U.S. FDA for Oteseconazole for the Treat

Search jobs
01-Jun-2021
Mycovia Pharmaceuticals Submits New Drug Application to the U.S. FDA for Oteseconazole for the Treatment of Recurrent Vulvovaginal Candidiasis
- NDA supported by positive data from VIOLET and ultraVIOLET Phase 3 clinical trials evaluating oteseconazole in more than 870 women in 11 countries -
- Oteseconazole’s Qualified Infectious Disease Product and Fast-Track designations allow for six-month priority review by FDA following its acceptance of the NDA -
DURHAM, N.C. (BUSINESS WIRE) Mycovia Pharmaceuticals, Inc. (“Mycovia”), an emerging biopharmaceutical company dedicated to recognizing and empowering those living with unmet medical needs by developing novel therapies, today announced it has submitted its New Drug Application (NDA) for oteseconazole, an oral antifungal product for the treatment of recurrent vulvovaginal candidiasis (RVVC). Also known as chronic yeast infection, RVVC is ....

United States , Hong Kong , Vulvovaginal Candidiasis , J Clin Microbiol , Thorsten Degenhardt , Anuj Baveja , Patrick Jordan , Mycovia Pharmaceuticals , Jiangsu Hengrui Medicine Co , Mycovia Pharmaceuticals Inc , Multicentre Study Group , Pharma Opportunities Fund , Gedeon Richter Plc , Qualified Infectious Disease Product , New Drug Application , Novaquest Capital Management , Chief Operating Officer , Infectious Disease Product , Independent States , Latin America , Product Finance , Eurj Clin Microbiol Infect , ஒன்றுபட்டது மாநிலங்களில் , ஹாங் காங் , அனுஜ் பாவேஜா , பேட்ரிக் ஜோர்டான் ,

NovaQuest Capital Management: Argenta Enters $30 Million Product Financing Agreement with NovaQuest to Accelerate New Veterinary Product Development

(0)
Argenta Limited ( Argenta ), the only global contract research organization (CRO) and contract development and manufacturing organization (CDMO) specializing in animal health, and NovaQuest Capital Management ( NovaQuest ) announced today a $30 million product financing agreement for the development of several innovative veterinary pharmaceuticals.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210520005132/en/
The collaboration leverages NovaQuest s capital and expertise, and Argenta s knowledge and know-how in research and development activities that advance animal health.
The capital investment from NovaQuest accelerates Argenta s strategy of providing innovative solutions and Molecule to Market services through global partnerships. We are delighted by the collaboration with NovaQuest and we look forward to strengthening our partnership through additional programs in the future, said Ben Russe ....

United States , New Zealand , United Kingdom , Ben Russell , Philip Nunes , Kostenloser Wertpapierhandel , Jonathan Tunnicliffe , Edward Mcgruder , Argenta Limited , Wyrick Robbins Yates Ponton , Pharma Opportunities Fund , Backbay Communications , Novaquest Capital Management , Chief Investment Officer , Brian Axe , Managing Director , Product Finance , Bay Communications , ஒன்றுபட்டது மாநிலங்களில் , புதியது ஜீலாந்து , ஒன்றுபட்டது கிஂக்டம் , பென் ரஸ்ஸல் , பிலிப் கன்னியாஸ்திரிகள் , ஜொனாதன் துண்னிகிலிப்பே , அர்ஜெண்டா வரையறுக்கப்பட்டவை , விரிக்க் ராபின்ஸ் யேட்ஸ் போந்டோன் ,

Argenta Enters $30 Million Product Financing Agreement with NovaQuest to Accelerate New Veterinary Product Development

Argenta Enters $30 Million Product Financing Agreement with NovaQuest to Accelerate New Veterinary Product Development
on May 20 2021 8:30 PM
RALEIGH, N.C. & AUCKLAND, New Zealand (BUSINESS WIRE) Argenta Limited (“Argenta”), the only global contract research organization (CRO) and contract development and manufacturing organization (CDMO) specializing in animal health, and NovaQuest Capital Management (“NovaQuest”) announced today a $30 million product financing agreement for the development of several innovative veterinary pharmaceuticals.
The collaboration leverages NovaQuest’s capital and expertise, and Argenta’s knowledge and know-how in research and development activities that advance animal health.
“The capital investment from NovaQuest accelerates Argenta’s strategy of providing innovative solutions and Molecule to Market services through global partnerships. We are delighted by the collaboration with NovaQuest and we look forward to strength ....

New Zealand , Back Bay , Western Australia , United States , United Kingdom , Ben Russell , Philip Nunes , Jonathan Tunnicliffe , Edward Mcgruder , Argenta Limited , Wyrick Robbins Yates Ponton , Pharma Opportunities Fund , Backbay Communications , Novaquest Capital Management , Chief Investment Officer , Brian Axe , Managing Director , Product Finance , புதியது ஜீலாந்து , மீண்டும் வளைகுடா , மேற்கு ஆஸ்திரேலியா , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , பென் ரஸ்ஸல் , பிலிப் கன்னியாஸ்திரிகள் , ஜொனாதன் துண்னிகிலிப்பே ,

Aceragen Launches with Acquisition of Enzyvant's Investigational Therapy for Farber Disease and $35 Million Product Financing with NovaQuest

Published: May 03, 2021
Acquires worldwide rights to RVT-801, a novel enzyme replacement therapy for treatment of Farber disease
NovaQuest investment to fund product and clinical development
Protocol for potential single registration study reviewed with FDA and EMA
Program has been granted rare pediatric disease status, fast track and orphan designations, and is eligible for a priority review voucher once approved
RESEARCH TRIANGLE PARK, N.C. & BASEL, Switzerland (BUSINESS WIRE)
Aceragen, Inc., a biopharmaceutical company focused on advancing transformational therapeutics for rare and ultra-rare diseases, today announced the acquisition of Enzyvant’s RVT-801 (now ACG-801), an investigational enzyme replacement therapy (ERT) for acid ceramidase deficiency presenting as Farber disease, a lysosomal storage disease with a unique, severe inflammatory phenotype for which no disease-specific therapy exists. Enzyvant will receive an upfront payment and dev ....

John Taylor , Ron Wooten , Hogan Lovells , Ed Schuchman , Spyryx Biosciences , Rachelle Jacques , Drug Administration , Arnold Porter , Aceragen Inc , Wyrick Robbins Yates Ponton , Icahn School Of Medicine At Mount Sinai , Pharma Opportunities Fund , Sumitomo Dainippon Pharma Co Ltd , Sumitovant Biopharma Ltd , Novaquest Capital Management , Chief Executive Officer , Icahn School , Mount Sinai , Spinal Muscular Atrophy , Progressive Myoclonic Epilepsy , Rare Pediatric Disease , Fast Track , Orphan Drug , Managing Partner Ron Wooten , Vice President Stephen Lesser , Product Finance ,

Cashing in on soaring market, NovaQuest acquires life science firm; Goldman Sachs helps

RALEIGH – With the global pandemic driving 7% annual growth in life science service companies, Raleigh-based NovaQuest Private Equity is getting in on the action. And it had help from Goldman Sachs in making a new deal.
Goldman Sachs Specialty Lending Group provided the debt financing NovaQuest needed to make the deal in which CoreRX becomes part of the NovaQuest portfolio. The deal was announced early Tuesday.
However, financial terms were not disclosed.
CoreX is a global contract development and manufacturing organization in Clearwater, Fla. It offers preformulation, formulation, analytical and stability, clinical manufacturing, commercial manufacturing, and packaging services.
NovaQuest
The deal comes as the market for life science firms such as several based in the Triangle is forecast to grow to more than $57 billion by 2025, according to a recent report. And that estimate was made before the full scale of the COVID-19 pandemic struck in 2019. ....

Ashton Poole , Jeff Edwards , Todd Daviau , Equity Fund , Pharma Opportunities Fund , Goldman Sachs , Goldman Sachs Specialty Lending Group , Raleigh Based Novaquest Private Equity , Sachs Specialty Lending Group , Private Equity Fund , Swiss Based Arvelle , Last August , Clinical Ink , ஆஷ்டன் பூல் , ஜெஃப் எட்வர்ட்ஸ் , பங்கு நிதி , பார்மா வாய்ப்புகள் நிதி , கோல்ட்மேன் சாக்ஸ் , கோல்ட்மேன் சாக்ஸ் சிறப்பு கடன் குழு , சாக்ஸ் சிறப்பு கடன் குழு , ப்ரைவேட் பங்கு நிதி , கடந்த ஆகஸ்ட் , மருத்துவ மை ,